Gabapentin Tablet, Film Coated
Product Images NDC 71610-426

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-426). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 800 mg (71610 0426 60)

Label for Gabapentin USP 800 mg film-coated tablets, 90 count, oral administration. The label shows the National Drug Code (NDC) 71610-0426-60 and states the product is manufactured by Strides Pharma Science Limited in Puducherry, India, and repackaged by Aphena Pharma Solutions in Cookeville, Tennessee. The label includes storage instructions and a barcode.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula for calculating creatinine clearance (CLCr), incorporating age, weight, serum creatinine levels, and a factor adjustment for female patients.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram of gabapentin, showing the molecular layout with a cyclohexane ring and amino and carboxyl functional groups.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period, while the y-axis shows the mean pain score. The graph shows the placebo group maintaining higher pain scores and the gabapentin group demonstrating a decrease over time.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph depicting mean pain scores over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis shows weeks from baseline to 7, and the y-axis shows mean pain scores from 0 to 10. The graph indicates a 3-week dose titration period followed by a 4-week fixed dose period, with gabapentin groups showing greater reductions in pain scores compared to placebo.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares response rates in Study 1 and Study 2 groups. Study 1 shows 12% for placebo (PBO) and 29% for Gabapentin (GBP) 3600 mg. Study 2 shows 14% for placebo and 32% and 34% for GBP 1800 mg and 2400 mg, respectively, with statistical significance indicated by p-values less than 0.01 and 0.001.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing percentage differences by daily dose (mg) across three studies labeled a, b, and c. The x-axis shows daily doses of 600, 900, 1200, and 1800 mg, while the y-axis shows percentage difference from 2% to 22%. The data points indicate variability of response or effect at each dose for studies a (black squares), b (gray squares), and c (white squares).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.